Английская Википедия:CVL-354

Материал из Онлайн справочника
Версия от 18:26, 13 февраля 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Chemical compound}} {{Infobox drug | drug_name = | image = | width = | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = | licence_US = | pregnancy_AU = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = Oral admin...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Infobox drug

CVL-354 is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders.[1][2]

It acts as a selective antagonist of the κ-opioid receptor.[1][2] The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor.[2] CVL-354 is taken by mouth.[1] It was originated by Pfizer and is under development by Cerevel Therapeutics.[1] As of September 2022, CVL-354 is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.[1]

See also

References

Шаблон:Reflist

Шаблон:Opioid receptor modulators


Шаблон:Nervous-system-drug-stub